Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells

Nutrition and Cancer

Volumn 65, Issue 2, 2013, Pages 286-295

  Moon, Jeong Yong ^a   Cho, Moonjae ^b   Ahn, Kwang Seok ^c   Cho, Somi Kim ^a  

^a Jeju National University   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLAVONOID; FLUOROURACIL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOBILETIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL PROLIFERATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STOMACH CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 9; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONES; FLUOROURACIL; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MUTATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874622060     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.756529     Document Type: Article

References (33)

1. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, et al.: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9, 279-287, 2008.
2. Ohtsu A: Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43, 256-264, 2008.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, et al.: Chemotherapy in advanced gastric cancer: a systematic reviewandmeta-analysis based on aggregate data. J Clin Oncol 24, 2903-2909, 2006.
4. Benson AB 3rd: New approaches to the adjuvant therapy of colon cancer. Oncologist 11, 973-980, 2006.
5. El-Shemy HA, Aboul-Enein AM, Aboul-Enein KM, and Fujita K: Willow leaves' extracts contain anti-tumor agents effective against three cell types. PLoS ONE 2, e178, 2007.
6. Park DJ and Lenz HJ: Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol 6, 337-344, 2006.
7. Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene 22, 9030-9040, 2003.
8. Lawen A: Apoptosis: an introduction. Bioessays 25,888-896, 2003.
9. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, et al.: Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4, 793-811, 2004.
10. Ramos S: Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52, 507-526, 2008.
11. Subapriya Rajamanickam RA: Natural products and colon cancer: current status and future prospects. Drug Dev Res 69, 460-471, 2008.
12. Moon JY,Kim H, ChoM,ChangWY,Kim CT, et al.: Induction of apoptosis in SNU-16 human gastric cancer cells by the chloroform fraction of an extract of Dangyuja (Citrus grandis) leaves. J Korean Soc Appl Biol Chem 52, 168-175, 2009.
13. Tang M, Ogawa K, Asamoto M, Hokaiwado N, Seeni A, et al.: Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci 98, 471-477, 2007.
14. Kawabata K, Murakami A, and Ohigashi H: Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci Biotechnol Biochem 69, 307-314, 2005.
15. Lee YC, Cheng TH, Lee JS, Chen JH, Liao YC, et al.: Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells. Mol Cell Biochem 347, 103-115, 2011.
16. LuoG,GuanX, and Zhou L: Apoptotic effect of citrus fruit extract nobiletin on lung cancer cell line A549 in vitro and in vivo. Cancer Biol Ther 7, 966-973, 2008.
17. Hector S and Prehn JH:Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta 1795, 117-129, 2009.
18. Benhattar J, Cerottini JP, Saraga E, Metthez G, and Givel JC: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69, 190-192, 1996.
19. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, et al.: Resistance of colon cancer cells to long-term 5-Xuorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98, 498-504, 2002.
20. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, et al.: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104, 263-269, 1999.
21. Adamsen BL, Kravik KL, Clausen OP, and De Angelis PM: Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-Xuorouracil treatment. Int J Oncol 31, 1491-1500, 2007.
22. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55, 1984.
23. Tounekti O, Belehradek J Jr, and Mir LM: Relationships between DNA fragmentation, chromatin condensation, and changes in flow cytometry profiles detected during apoptosis. Exp Cell Res 217, 506-516, 1995
24. Fernandes-Alnemri T, Litwack G, and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269, 30761-30764, 1994.
25. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, and EarnshawWC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371, 346-347, 1994.
26. Harper JW, Adami GR, Wei N, Keyomarsi K, and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816, 1993.
27. Pan MH, Chen WJ, Lin-Shiau SY, Ho CT, and Lin JK: Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors P21 and P27 in human colorectal carcinoma cells. Carcinogenesis 23, 1677-1684, 2002.
28. Phromnoi K, Reuter S, Sung B, Limtrakul P, and Aggarwal BB: A dihydroxy-pentamethoxyflavone from Gardenia obtusifolia suppresses proliferation and promotes apoptosis of tumor cells through modulation of multiple cell signaling pathways. Anticancer Res 30, 3599-3610, 2010.
29. B́eroud C and Soussi T: The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21, 176-181, 2003.
30. Magali Olivier RE, Hollstein M, Khan MA, Harris CC, and Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19, 607-614, 2002.
31. Bae IH, Kang SW, Yoon SH, and Um HD: Cellular components involved in the cell death induced by cisplatin in the absence of p53 activation. Oncol Rep 15, 1175-1180, 2006.
32. Lee BJ, Chon KM, Kim YS, An WG, Roh HJ, et al.: Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line. Chemotherapy 51, 103-110, 2005
33. Seo JS, Kim TG, Hong YS, Chen JY, and Lee SK: Contribution of Epstein-Barr virus infection to chemoresistance of gastric carcinoma cells to 5-fluorouracil. Arch Pharm 34, 635-643, 2011.